Picture loading failed.

Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Itolizumab (INN, trade name Alzumab) is a "first in class" humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-284-1mg 1mg 3090
GMP-Bios-ab-284-10mg 10mg Inquiry
GMP-Bios-ab-284-100mg 100mg Inquiry
GMP-Bios-ab-284-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody
INN Name Itolizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesCenter of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium
Conditions ApprovedPlaque psoriasis
Conditions ActiveGraft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis
Conditions DiscontinuedAutoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis
Development Techna